- Imugene has appointed Dr Rita Laeufle as its new Chief Medical Officer and a member of its executive leadership team.
- Dr Laeufle will lead the Company’s global clinical development, medical monitoring, and regulatory activities.
- Dr Laeufle holds extensive clinical development experience as a board-certified surgical oncologist and a scientist.
- Imugene’s Executive Chairman, Mr Paul Hopper believes Dr Laeufle adds a critical capability to the Company’s senior leadership team.
- Imugene is actively continuing with four clinical programs, associated with CHECKvacc (CF33 & anti-PDL1), VAXinia (CF33), PD1-Vaxx (PD-1) and HER-Vaxx (HER-2).
Clinical stage immuno-oncology company based in Australia, Imugene Limited (ASX:IMU) has recently announced the appointment of its new Chief Medical Officer (CMO). Imugene notified that it has hired Dr Rita Laeufle, MD PhD, as the CMO of the Company and a member of its executive leadership team.
Imugene shares traded at $0.051, up 8.5% mid-day on 1 October 2020.
Dr Laeufle has replaced Dr Mark Marino and will lead the Company’s global clinical development, medical monitoring, and regulatory activities. Dr Laeufle holds Doctor of Philosophy and Medical Doctor and degrees from Germany-based Albert Ludwig University of Freiburg. She studied the expression of neu/c-erbB-2 (HER-2) in human brain tumors as her PhD subject (Magna cum Laude).
Addition of Deep Experience to Imugene’s Leadership team
Dr Laeufle holds extensive clinical development experience as a board-certified surgical oncologist and a scientist. She has experience in immuno-oncology studies from Phase 1 to Phase 3 in gastrointestinal and breast cancers registration pathways.
Besides, she has held senior level clinical development, senior medical and leadership positions at multiple top-grade pharmaceutical companies, including Novartis Pharmaceuticals Corp and Hoffman-La Roche AG. Most recently, she was the CMO of a leading oncolytic virus firm based in San Diego CA, Oncolytics Biotech, where she will be based.
Imugene’s Executive Chairman, Mr Paul Hopper believes Dr Laeufle adds a critical capability to the Company’s senior leadership team.
Welcoming Dr Laeufle onboard, Imugene’s Managing Director and CEO, Ms Leslie Chong, said:
Dr Laeufle Enthusiastic to Join Imugene
Dr Laeufle is also excited to join the team of experts at Imugene that boasts a robust pipeline of innovative immunotherapy vaccines and oncolytic viruses.
Dr Laeufle believes that our understanding and knowledge of cancer biology has reached new dimensions in the present world. According to her, scientists across the world, with their enthusiasm and passion, have provided us with a future of novel immunotherapy agents that will assist cure and relieve the burden of the dreadful disease. By joining Imugene, she intends to drive towards safer and better treatments for the benefit of cancer patients.
Imugene is actively continuing with four clinical programs, associated with CHECKvacc (CF33 & aPDL1), VAXinia (CF33), PD1-Vaxx (PD-1) and HER-Vaxx (HER-2). The Company has recently secured option underwriting agreement with Bell Potter to raise ~$5.7 million to support its four progressing clinical programs.
Imugene believes that immunotherapies will continue to remain a foundation treatment for cancer disease over the coming years. Imugene’s goal is to ensure that the Company and its shareholders are at the vanguard of this fast-developing global market.